|
KR100508289B1
(ko)
*
|
1998-04-21 |
2005-08-17 |
마이크로메트 에이지 |
Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
|
|
ATE311199T1
(de)
|
1999-05-07 |
2005-12-15 |
Genentech Inc |
Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
|
|
US8119101B2
(en)
|
1999-05-10 |
2012-02-21 |
The Ohio State University |
Anti-CD74 immunoconjugates and methods of use
|
|
US7829064B2
(en)
|
1999-05-10 |
2010-11-09 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods
|
|
US8383081B2
(en)
|
1999-05-10 |
2013-02-26 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods of use
|
|
EP1543839B1
(en)
*
|
1999-06-09 |
2017-09-20 |
Immunomedics, Inc. |
Immunotherapy of autoimmune disorders using antibodies which target B-cells
|
|
AU782160B2
(en)
*
|
1999-06-09 |
2005-07-07 |
Immunomedics Inc. |
Immunotherapy of autoimmune disorders using antibodies which target B-cells
|
|
DE19962583A1
(de)
*
|
1999-12-23 |
2001-06-28 |
Mueller Hermelink Hans Konrad |
Antikörper gegen Plasmazellen
|
|
US7446179B2
(en)
|
2000-11-07 |
2008-11-04 |
City Of Hope |
CD19-specific chimeric T cell receptor
|
|
US20080260731A1
(en)
*
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
|
US9453251B2
(en)
|
2002-10-08 |
2016-09-27 |
Pfenex Inc. |
Expression of mammalian proteins in Pseudomonas fluorescens
|
|
US7820166B2
(en)
|
2002-10-11 |
2010-10-26 |
Micromet Ag |
Potent T cell modulating molecules
|
|
RU2005141512A
(ru)
*
|
2003-05-31 |
2007-07-20 |
Микромет Аг (De) |
Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками
|
|
DE602004025101D1
(de)
|
2003-05-31 |
2010-03-04 |
Micromet Ag |
Humane anti-humane cd3-bindungsmoleküle
|
|
WO2005048917A2
(en)
|
2003-06-06 |
2005-06-02 |
Medimmune, Inc. |
Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer
|
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
|
EP2216342B1
(en)
*
|
2003-07-31 |
2015-04-22 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
|
ES2358427T3
(es)
|
2003-10-16 |
2011-05-10 |
Micromet Ag |
Elementos de unión a cd-3 desinmunizados multiespecíficos.
|
|
ATE459374T1
(de)
*
|
2003-11-28 |
2010-03-15 |
Micromet Ag |
Polypeptide enthaltende zusammensetzungen
|
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
|
US8883160B2
(en)
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
DE602005022830D1
(de)
*
|
2004-02-16 |
2010-09-23 |
Micromet Ag |
Weniger immunogene bindungsmoleküle
|
|
EP1774017B1
(en)
|
2004-07-26 |
2013-05-15 |
Pfenex Inc. |
Process for improved protein expression by strain engineering
|
|
JP2008518023A
(ja)
|
2004-10-27 |
2008-05-29 |
メディミューン，インコーポレーテッド |
同族抗原に対する親和性を改変することによる抗体特異性の調節
|
|
CA2597924C
(en)
*
|
2005-02-15 |
2018-10-02 |
Duke University |
Anti-cd19 antibodies and uses in oncology
|
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
|
RS54127B1
(en)
|
2005-04-18 |
2015-12-31 |
Amgen Research (Munich) Gmbh |
ANTIBODIES NEUTRALIZERS OF THE HUMAN FACTOR OF STIMULATION OF THE COLONIA OF THE GRANULLocyte MACROPHAGUS
|
|
CA2606081C
(en)
|
2005-04-26 |
2013-09-17 |
Markus M. Heiss |
Combination of the application of antibodies for immunostimulation together with glucocorticoids
|
|
JP5215180B2
(ja)
|
2005-06-20 |
2013-06-19 |
メダレックス インコーポレーティッド |
Ｃｄ１９抗体およびその使用法
|
|
WO2007024715A2
(en)
*
|
2005-08-19 |
2007-03-01 |
Abbott Laboratories |
Dual variable domain immunoglobin and uses thereof
|
|
ES2856451T3
(es)
|
2005-10-11 |
2021-09-27 |
Amgen Res Munich Gmbh |
Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas
|
|
JP5442998B2
(ja)
*
|
2005-12-16 |
2014-03-19 |
アムゲン リサーチ （ミュンヘン） ゲーエムベーハー |
腫瘍性疾患を処置するための手段および方法
|
|
BRPI0620632A2
(pt)
|
2005-12-21 |
2011-12-20 |
Micromet Ag |
composições farmacêuticas com resistência a cea solúvel, processo de produção das mesmas, usos de anticorpo bi-especìfico de cadeia simples, molécula de ácido nucléico, vetor e hospedeiro na preparação de composição farmacêuticas, e kits
|
|
US20090221024A1
(en)
*
|
2006-03-02 |
2009-09-03 |
Antitope Limited |
T cell assays
|
|
US8524867B2
(en)
|
2006-08-14 |
2013-09-03 |
Xencor, Inc. |
Optimized antibodies that target CD19
|
|
WO2008031056A2
(en)
*
|
2006-09-08 |
2008-03-13 |
Medimmune, Llc |
Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
KR101940944B1
(ko)
†
|
2007-04-03 |
2019-01-22 |
암젠 리서치 (뮌헨) 게엠베하 |
종간 특이적 ｃｄ３―입실론 결합 도메인
|
|
KR101626988B1
(ko)
*
|
2007-04-03 |
2016-06-02 |
암젠 리서치 (뮌헨) 게엠베하 |
종간 특이적 이중특이적인 결합제들
|
|
HUE040467T2
(hu)
|
2007-04-03 |
2019-03-28 |
Amgen Res Munich Gmbh |
Keresztfaj-specifikus kötõdomén
|
|
US9394571B2
(en)
|
2007-04-27 |
2016-07-19 |
Pfenex Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
|
US9580719B2
(en)
|
2007-04-27 |
2017-02-28 |
Pfenex, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
|
KR20190140090A
(ko)
|
2007-07-09 |
2019-12-18 |
제넨테크, 인크. |
폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
|
|
EP2069401A4
(en)
*
|
2007-07-31 |
2011-02-23 |
Medimmune Llc |
MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE
|
|
US9096832B2
(en)
*
|
2007-07-31 |
2015-08-04 |
Lifescan, Inc. |
Differentiation of human embryonic stem cells
|
|
SI2211904T1
(sl)
*
|
2007-10-19 |
2016-12-30 |
Seattle Genetics, Inc. |
CD19 vezavna sredstva in njihove uporabe
|
|
JP5490714B2
(ja)
*
|
2007-11-28 |
2014-05-14 |
メディミューン，エルエルシー |
タンパク質製剤
|
|
US20110293619A1
(en)
|
2008-10-01 |
2011-12-01 |
Micromet Ag |
CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
|
|
EP3375790A1
(en)
|
2008-10-01 |
2018-09-19 |
Amgen Research (Munich) GmbH |
Cross-species-specific single domain bispecific single chain antibody
|
|
BRPI0919840B1
(pt)
*
|
2008-10-01 |
2023-02-28 |
Amgen Research (Munich) Gmbh |
Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende
|
|
WO2010037837A2
(en)
|
2008-10-01 |
2010-04-08 |
Micromet Ag |
Bispecific single chain antibodies with specificity for high molecular weight target antigens
|
|
JP5647132B2
(ja)
|
2008-11-07 |
2014-12-24 |
アムゲン リサーチ （ミュンヘン） ゲーエムベーハー |
急性リンパ芽球性白血病の治療
|
|
DK3330293T3
(da)
|
2008-11-07 |
2019-10-07 |
Amgen Res Munich Gmbh |
Behandling af pædiatrisk akut lymfoblastær leukæmi med bispecifikke antistoffer mod CD3xCD19
|
|
US8993808B2
(en)
|
2009-01-21 |
2015-03-31 |
Oryzon Genomics, S.A. |
Phenylcyclopropylamine derivatives and their medical use
|
|
US9676845B2
(en)
*
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
JP2012531418A
(ja)
|
2009-06-23 |
2012-12-10 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
補体タンパク質に結合する二重特異性抗体
|
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
RU2602814C2
(ru)
|
2009-09-25 |
2016-11-20 |
Оризон Дженомикс С.А. |
Лизинспецифические ингибиторы деметилазы-1 и их применение
|
|
WO2011042217A1
(en)
|
2009-10-09 |
2011-04-14 |
Oryzon Genomics S.A. |
Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
|
|
PL2493503T5
(pl)
|
2009-10-27 |
2021-05-31 |
Amgen Research (Munich) Gmbh |
Schemat dawkowania do podawania dwuswoistego przeciwciała CD19xCD3
|
|
WO2011069104A2
(en)
|
2009-12-04 |
2011-06-09 |
Genentech, Inc. |
Multispecific antibodies, antibody analogs, compositions, and methods
|
|
TW201125583A
(en)
*
|
2009-12-23 |
2011-08-01 |
Bioalliance Cv |
Anti-EpCAM antibodies that induce apoptosis of cancer cells and methods using same
|
|
WO2011106573A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
|
|
US9616058B2
(en)
|
2010-02-24 |
2017-04-11 |
Oryzon Genomics, S.A. |
Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
|
|
TWI653333B
(zh)
|
2010-04-01 |
2019-03-11 |
安進研究（慕尼黑）有限責任公司 |
跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
|
|
PT2560947T
(pt)
|
2010-04-19 |
2016-11-24 |
Oryzon Genomics Sa |
Inibidores da desmetilase específica de lisina 1 e seu uso
|
|
SG185027A1
(en)
|
2010-05-03 |
2012-11-29 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor
|
|
JP5636091B2
(ja)
|
2010-05-05 |
2014-12-03 |
ウニベルジテート バイロイト |
癌治療に用いるためのコンブレタスタチン類似体
|
|
CN102250245B
(zh)
*
|
2010-05-27 |
2014-05-14 |
四川大学 |
抗b细胞淋巴瘤的双特异性抗体及其用途
|
|
US20130123367A1
(en)
|
2010-07-28 |
2013-05-16 |
Medizinische Universitat Wien |
Vinylogous chalcone derivatives and their medical use
|
|
EP2598480B1
(en)
|
2010-07-29 |
2019-04-24 |
Oryzon Genomics, S.A. |
Cyclopropylamine derivatives useful as lsd1 inhibitors
|
|
EP2598530A2
(en)
|
2010-07-29 |
2013-06-05 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
DK2598482T3
(en)
|
2010-07-29 |
2018-06-14 |
Oryzon Genomics Sa |
ARYLCYCLOPROPYLAMINE-BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE
|
|
US9061966B2
(en)
|
2010-10-08 |
2015-06-23 |
Oryzon Genomics S.A. |
Cyclopropylamine inhibitors of oxidases
|
|
ME02311B
(me)
|
2010-10-27 |
2016-06-20 |
Amgen Res Munich Gmbh |
Sredstva za liječenje i postupci liječenja dlbcl
|
|
EP3831386A1
(en)
*
|
2010-11-10 |
2021-06-09 |
Amgen Research (Munich) GmbH |
Prevention of adverse effects caused by cd3 specific binding domains
|
|
WO2012066058A1
(en)
|
2010-11-16 |
2012-05-24 |
Boehringer Ingelheim International Gmbh |
Agents and methods for treating diseases that correlate with bcma expression
|
|
WO2012072713A2
(en)
|
2010-11-30 |
2012-06-07 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
|
|
EP3981395A1
(en)
|
2011-02-08 |
2022-04-13 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for myeloproliferative disorders
|
|
WO2012109624A2
(en)
|
2011-02-11 |
2012-08-16 |
Zyngenia, Inc. |
Monovalent and multivalent multispecific complexes and uses thereof
|
|
CN103648529A
(zh)
|
2011-04-28 |
2014-03-19 |
安进研发（慕尼黑）股份有限公司 |
用于给处于潜在不良反应的风险的患者施用CD19xCD3双特异性抗体的给药方案
|
|
NZ703939A
(en)
|
2011-05-21 |
2016-01-29 |
Macrogenics Inc |
Cd3-binding molecules capable of binding to human and non-human cd3
|
|
EP2714738B1
(en)
|
2011-05-24 |
2018-10-10 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
|
RU2708977C2
(ru)
|
2011-06-10 |
2019-12-12 |
МЕДИММЬЮН, ЭлЭлСи |
Молекулы, связывающиеся с psl pseudomonas, и пути их применения
|
|
SG10201606785UA
(en)
*
|
2011-08-16 |
2016-10-28 |
Morphosys Ag |
Combination therapy with an anti - cd19 antibody and a nitrogen mustard
|
|
DE102012016127A1
(de)
|
2011-08-31 |
2013-02-28 |
Daniel Elias |
Bioaktive, regenerative Mischung zur Herstellung eines Ergänzungsnahrungsmittels
|
|
EP2758438A1
(en)
|
2011-09-23 |
2014-07-30 |
Amgen Research (Munich) GmbH |
Bispecific binding molecules for 5t4 and cd3
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
CA2849564C
(en)
|
2011-10-20 |
2020-10-20 |
Oryzon Genomics, S.A. |
(hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
|
|
EP2768805B1
(en)
|
2011-10-20 |
2020-03-25 |
Oryzon Genomics, S.A. |
(hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
|
|
PL2776065T3
(pl)
|
2011-11-07 |
2020-12-14 |
Medimmune Limited |
Terapie skojarzone z zastosowaniem cząsteczek wiążących przeciwko psl i pcrv pseudomonas
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
|
EP2788020A4
(en)
|
2011-12-05 |
2015-04-29 |
Immunomedics Inc |
THERAPEUTIC USE OF ANTI-CD22 ANTIBODIES FOR THE INDUCTION OF TROGO CYTOSIS
|
|
US10633451B2
(en)
*
|
2012-02-03 |
2020-04-28 |
Hoffmann-La Roche Inc. |
Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine
|
|
EP2817318A4
(en)
|
2012-02-22 |
2016-04-27 |
Univ Pennsylvania |
COMPOSITIONS AND METHOD FOR GENERATING A PERSISTENT POPULATION OF T CELLS FOR CANCER TREATMENT
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
CA2864177C
(en)
|
2012-03-01 |
2019-11-26 |
Amgen Research (Munich) Gmbh |
Prolonged half-life albumin-binding protein fused bispecific antibodies
|
|
CN103382223B
(zh)
|
2012-04-01 |
2015-06-10 |
上海益杰生物技术有限公司 |
针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
|
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
|
JP2015524255A
(ja)
|
2012-07-13 |
2015-08-24 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
二重特異性抗体を共導入することによってｃａｒｔ細胞の活性を強化する方法
|
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
WO2014028560A2
(en)
|
2012-08-14 |
2014-02-20 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
US20150231241A1
(en)
|
2012-08-14 |
2015-08-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
US10131712B2
(en)
|
2012-08-14 |
2018-11-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
AR093297A1
(es)
|
2012-10-31 |
2015-05-27 |
Amgen Res (Munich) Gmbh |
Formulacion liquida que comprende un compuesto neutralizante de gm-csf
|
|
WO2014068029A1
(en)
|
2012-10-31 |
2014-05-08 |
Takeda Gmbh |
Lyophilized formulation comprising gm-csf neutralizing compound
|
|
CN103833852A
(zh)
*
|
2012-11-23 |
2014-06-04 |
上海市肿瘤研究所 |
针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
|
|
US9107960B2
(en)
|
2012-12-13 |
2015-08-18 |
Immunimedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
|
HRP20220399T1
(hr)
|
2012-12-13 |
2022-05-13 |
Immunomedics, Inc. |
Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost
|
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
KR102211837B1
(ko)
|
2013-01-14 |
2021-02-03 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
EP2945969A1
(en)
|
2013-01-15 |
2015-11-25 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
CN103965359B
(zh)
*
|
2013-01-24 |
2016-08-03 |
上海市肿瘤研究所 |
抗上皮细胞粘附分子和t细胞抗原的双特异性抗体
|
|
ES2728936T3
(es)
|
2013-01-25 |
2019-10-29 |
Amgen Inc |
Anticuerpos dirigidos contra CDH19 para melanoma
|
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
|
US9486475B2
(en)
|
2013-02-08 |
2016-11-08 |
Amgen Research (Munich) Gmbh |
PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
|
|
JO3529B1
(ar)
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
|
CA2903096A1
(en)
|
2013-03-05 |
2014-09-12 |
Baylor College Of Medicine |
Oncolytic virus
|
|
JP6420776B2
(ja)
|
2013-03-05 |
2018-11-07 |
ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ |
免疫療法のためのエンゲージャー細胞
|
|
US9505849B2
(en)
|
2013-03-15 |
2016-11-29 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza M2 and CD3
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
WO2014140358A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Research (Munich) Gmbh |
Single chain binding molecules comprising n-terminal abp
|
|
CA3093606A1
(en)
|
2013-03-15 |
2014-09-18 |
Xencor, Inc. |
Heterodimeric proteins for induction of t cells
|
|
MX2015013163A
(es)
|
2013-03-15 |
2016-04-04 |
Zyngenia Inc |
Complejos multiespecificos multivalente y monovalentes y sus usos.
|
|
US20140302037A1
(en)
*
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res (Munich) Gmbh |
Moléculas de unión para bcma y cd3
|
|
JP6480907B2
(ja)
*
|
2013-03-15 |
2019-03-13 |
メモリアル スローン ケタリング キャンサー センター |
多量体化技術
|
|
US9561291B2
(en)
*
|
2013-03-15 |
2017-02-07 |
Imre Kovesdi |
Methods of targeting T-cells to tumors
|
|
CN104140974B
(zh)
*
|
2013-05-08 |
2017-09-29 |
科济生物医药（上海）有限公司 |
编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
|
|
EP3415534A1
(en)
|
2013-05-10 |
2018-12-19 |
Numab Therapeutics AG |
Bispecific constructs and their use in the treatment of various diseases
|
|
AU2014287244B2
(en)
*
|
2013-07-09 |
2017-06-15 |
Duke University |
Certain improved human bispecific EGFRvIII antibody engaging molecules
|
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
CN104342453A
(zh)
*
|
2013-08-06 |
2015-02-11 |
深圳先进技术研究院 |
含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
|
|
KR20220045064A
(ko)
|
2013-08-30 |
2022-04-12 |
다케다 야쿠힌 고교 가부시키가이샤 |
류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체
|
|
AR097648A1
(es)
|
2013-09-13 |
2016-04-06 |
Amgen Inc |
Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
|
|
CN105813654B
(zh)
|
2013-10-11 |
2019-05-31 |
美国政府(由卫生和人类服务部的部长所代表) |
Tem8抗体及其用途
|
|
CN104623637A
(zh)
|
2013-11-07 |
2015-05-20 |
健能隆医药技术（上海）有限公司 |
Il-22二聚体在制备静脉注射药物中的应用
|
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
WO2015126548A1
(en)
|
2014-02-21 |
2015-08-27 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to trop-2 expressing cells
|
|
CA2935748A1
(en)
|
2014-02-25 |
2015-09-03 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
WO2015149077A1
(en)
|
2014-03-28 |
2015-10-01 |
Xencor, Inc. |
Bispecific antibodies that bind to cd38 and cd3
|
|
RU2577226C2
(ru)
*
|
2014-04-10 |
2016-03-10 |
Общество с ограниченной ответственностью, "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") |
Способ получения биспецифических антител против cd3*cd19 формата флексибоди в клетках млекопитающих
|
|
RU2568910C2
(ru)
*
|
2014-04-18 |
2015-11-20 |
Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") |
Фармацевтические композиции на основе флексибоди против cd3*cd19 для лечения в-клеточных заболеваний
|
|
CN105017422A
(zh)
*
|
2014-04-30 |
2015-11-04 |
山东百因制药技术有限公司 |
一种抗cd3/抗cd19双特异性抗体及其应用
|
|
CA2946230A1
(en)
|
2014-05-07 |
2015-11-12 |
Takeda Gmbh |
Liquid formulation comprising gm-csf neutralizing compound
|
|
WO2015172341A1
(zh)
*
|
2014-05-14 |
2015-11-19 |
上海市肿瘤研究所 |
针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
|
|
EP2947460A1
(en)
|
2014-05-22 |
2015-11-25 |
Medizinische Universität Wien |
Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
|
|
CA2948771C
(en)
|
2014-05-30 |
2023-10-17 |
Amgen Research (Munich) Gmbh |
Risk-stratification of b-precursor acute lymphoblastic leukemia patients
|
|
EP3164417A1
(en)
|
2014-07-01 |
2017-05-10 |
Pfizer Inc. |
Bispecific heterodimeric diabodies and uses thereof
|
|
EP3172235A2
(en)
|
2014-07-25 |
2017-05-31 |
Cytomx Therapeutics Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
AR101936A1
(es)
|
2014-07-31 |
2017-01-25 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos de cadena sencilla biespecífica específicos para especies cruzadas optimizadas
|
|
ES2980787T3
(es)
|
2014-07-31 |
2024-10-03 |
Amgen Res Munich Gmbh |
Constructo de anticuerpo de cadena sencilla biespecífico con distribución tisular potenciada
|
|
UY36245A
(es)
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
|
US10280156B2
(en)
|
2014-08-28 |
2019-05-07 |
Medizinische Universität Wien |
Heteroaromatic chalcone derivatives and their medical use
|
|
WO2016077789A1
(en)
|
2014-11-14 |
2016-05-19 |
The Usa, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
|
MX2017006312A
(es)
|
2014-11-17 |
2017-08-21 |
Regeneron Pharma |
Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20.
|
|
PE20171324A1
(es)
|
2014-11-26 |
2017-09-11 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
|
|
AU2015353416C1
(en)
|
2014-11-26 |
2022-01-27 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and CD38
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
EP3029067A1
(en)
|
2014-12-01 |
2016-06-08 |
Deutsches Krebsforschungszentrum |
Use of blocking-reagents for reducing unspecific T cell-activation
|
|
WO2016094834A2
(en)
|
2014-12-12 |
2016-06-16 |
Alexion Pharmaceuticals, Inc. |
A method for treating a complement mediated disorder caused by an infectious agent in a patient
|
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
|
AU2016210068B2
(en)
|
2015-01-23 |
2021-10-28 |
Sanofi |
Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123
|
|
WO2016135139A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
|
WO2016135138A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
|
|
JP6959869B2
(ja)
|
2015-02-23 |
2021-11-05 |
シーガル セラピューティクス エスアーエス |
非天然セマフォリン３およびそれらの医学的使用
|
|
WO2016135137A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
|
WO2016135140A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
|
|
WO2016138160A1
(en)
|
2015-02-24 |
2016-09-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
|
|
CN107580603A
(zh)
|
2015-02-24 |
2018-01-12 |
生物蛋白有限公司 |
条件活性生物蛋白
|
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
EP3064507A1
(en)
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
|
|
US10562960B2
(en)
|
2015-03-20 |
2020-02-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to gp120 and their use
|
|
WO2016164558A1
(en)
*
|
2015-04-07 |
2016-10-13 |
Children's Medical Center Corporation |
Methods and compositions relating to an embryonic stem cell-based tumor model
|
|
MA43197A
(fr)
|
2015-04-17 |
2018-09-19 |
Amgen Res Munich Gmbh |
Constructions d'anticorps bispécifiques pour cdh3 et cd3
|
|
CA2981543A1
(en)
|
2015-04-22 |
2016-10-27 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
|
WO2016170102A1
(en)
|
2015-04-22 |
2016-10-27 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
|
|
WO2016180982A1
(en)
|
2015-05-13 |
2016-11-17 |
Ablynx N.V. |
T cell recruiting polypeptides based on cd3 reactivity
|
|
EP3294768B1
(en)
|
2015-05-13 |
2019-08-21 |
Ablynx N.V. |
T cell recruiting polypeptides based on tcr alpha/beta reactivity
|
|
AU2016271113B2
(en)
|
2015-05-29 |
2022-09-08 |
Amphivena Therapeutics, Inc. |
Methods of using bispecific CD33 and CD3 binding proteins
|
|
WO2016196975A1
(en)
|
2015-06-03 |
2016-12-08 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
|
CN106349391A
(zh)
*
|
2015-07-17 |
2017-01-25 |
中国科学院深圳先进技术研究院 |
Hbv特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环dna及应用
|
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究（慕尼黑）公司 |
Dll3及cd3抗體構築體
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究（慕尼黑）公司 |
Ｃｄ７０及ｃｄ３抗體構築體
|
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
|
MX2018002226A
(es)
|
2015-08-28 |
2018-03-23 |
Amunix Operating Inc |
Ensamble de polipeptido quimerico y metodos para hacer y usar el mismo.
|
|
EP3328885A1
(en)
|
2015-09-11 |
2018-06-06 |
Bruce Andrien |
Recombinant glycosylated eculizumab and eculizumab variants
|
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
|
RU2022108079A
(ru)
|
2015-09-24 |
2022-04-08 |
Дайити Санкио Компани, Лимитед |
Антитело против garp
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
EP3356407B1
(en)
|
2015-10-02 |
2021-11-03 |
F. Hoffmann-La Roche AG |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
WO2017062649A1
(en)
|
2015-10-07 |
2017-04-13 |
Alexion Pharmaceuticals, Inc. |
A method for treating age-related macular degeneration in a patient
|
|
EP3359570A1
(en)
|
2015-10-07 |
2018-08-15 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
|
|
EP3371349A4
(en)
|
2015-11-02 |
2018-09-12 |
Bioatla, LLC |
Conditionally active polypeptides
|
|
WO2017079479A1
(en)
|
2015-11-03 |
2017-05-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human |
Neutralizing antibodies to hiv-1 gp41 and their use
|
|
CN105296421B
(zh)
*
|
2015-11-24 |
2019-01-29 |
高岱清 |
一种双特异性抗体活化的t细胞及制备方法与应用
|
|
RU2651776C2
(ru)
*
|
2015-12-01 |
2018-04-23 |
Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") |
Биспецифические антитела против cd3*cd19
|
|
AU2016365742A1
(en)
|
2015-12-07 |
2018-06-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
|
HUE056897T2
(hu)
|
2015-12-09 |
2022-03-28 |
Univ Wien Med |
Monomaleimid-funkcionalizált platinavegyületek rákterápiához
|
|
KR102424513B1
(ko)
|
2015-12-14 |
2022-07-25 |
마크로제닉스, 인크. |
Pd-1 및 ctla-4과의 면역반응성을 가진 이중특이적 분자, 및 이것의 사용 방법
|
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
SG11201806150RA
(en)
|
2016-02-03 |
2018-08-30 |
Amgen Res Munich Gmbh |
Psma and cd3 bispecific t cell engaging antibody constructs
|
|
BR112018015715A2
(pt)
|
2016-02-03 |
2019-02-05 |
Amgen Inc |
construtos de anticorpo de engate de célula t biespecífica bcma e cd3
|
|
CA3011372A1
(en)
|
2016-02-10 |
2017-08-17 |
Immunomedics, Inc. |
Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
|
|
AU2017220611A1
(en)
|
2016-02-15 |
2018-08-30 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
TAF1 inhibitors for the therapy of cancer
|
|
EP3216458A1
(en)
|
2016-03-07 |
2017-09-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modified vascular endothelial growth factor a (vegf-a) and its medical use
|
|
US12128102B2
(en)
|
2016-03-08 |
2024-10-29 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
CA3018382A1
(en)
|
2016-03-29 |
2017-10-05 |
University Of Southern California |
Chimeric antigen receptors targeting cancer
|
|
WO2017167350A1
(en)
*
|
2016-03-30 |
2017-10-05 |
Horst Lindhofer |
Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract
|
|
WO2017178572A1
(en)
*
|
2016-04-13 |
2017-10-19 |
Vivia Biotech, S.L |
Ex vivo bite-activated t cells
|
|
CN109328069B
(zh)
|
2016-04-15 |
2023-09-01 |
亿一生物医药开发(上海)有限公司 |
Il-22在治疗坏死性小肠结肠炎中的用途
|
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
|
CN109310385A
(zh)
|
2016-04-27 |
2019-02-05 |
免疫医疗公司 |
抗trop-2-sn-38抗体药物缀合物用于检查点抑制剂复发/难治的肿瘤的疗法的功效
|
|
WO2017192589A1
(en)
|
2016-05-02 |
2017-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to influenza ha and their use and identification
|
|
CN105906720A
(zh)
*
|
2016-05-16 |
2016-08-31 |
武汉汉密顿生物科技股份有限公司 |
靶向性嵌合抗原受体修饰的免疫细胞及其制备方法和应用
|
|
IL263542B2
(en)
|
2016-06-14 |
2024-10-01 |
Xencor Inc |
Bispecific antibodies inhibit immunological checkpoint
|
|
US10669338B2
(en)
|
2016-06-17 |
2020-06-02 |
Immunomedics, Inc. |
Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
|
|
EP4050032A1
(en)
|
2016-06-28 |
2022-08-31 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
|
CA3029426A1
(en)
|
2016-06-30 |
2018-01-04 |
Oncorus, Inc. |
Pseudotyped oncolytic viral delivery of therapeutic polypeptides
|
|
TWI790206B
(zh)
|
2016-07-18 |
2023-01-21 |
法商賽諾菲公司 |
特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
|
|
US11584780B2
(en)
|
2016-07-26 |
2023-02-21 |
Biomarin Pharmaceutical Inc. |
Adeno-associated virus capsid proteins
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
WO2018049261A1
(en)
|
2016-09-09 |
2018-03-15 |
Icellhealth Consulting Llc |
Oncolytic virus expressing immune checkpoint modulators
|
|
US20190307799A1
(en)
|
2016-09-23 |
2019-10-10 |
The Regents Of The University Of Michigan |
Engineered lymphocytes
|
|
MX2019004327A
(es)
|
2016-10-14 |
2019-10-14 |
Xencor Inc |
Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
|
|
JP7096240B2
(ja)
|
2016-10-19 |
2022-07-05 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
試料中の非結合ｃ５の定量化方法
|
|
JP2020511401A
(ja)
|
2016-11-14 |
2020-04-16 |
チェム−フォルシュングスツェントルン フュル モレクラーレ メディツィン ゲゼルシャフト ミット ベシュレンクテル ハフツング |
癌の治療法のためのｂｒｄ４阻害剤と葉酸代謝拮抗薬との組み合わせ物
|
|
JP7222888B2
(ja)
|
2016-11-16 |
2023-02-15 |
アブリンクス エン．ヴェー． |
Ｃｄ１２３及びｔｃｒアルファ／ベータに結合することが可能なｔ細胞動員ポリペプチド
|
|
JP2020503015A
(ja)
*
|
2016-12-13 |
2020-01-30 |
カースゲン セラピューティクス リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ |
抗ｃｄ１９のヒト化抗体及びｃｄ１９を標的とする免疫エフェクター細胞
|
|
CN108264566B
(zh)
*
|
2016-12-30 |
2021-05-14 |
惠和生物技术(上海)有限公司 |
一种融合抗cd3抗体结构域和t细胞正共刺激分子配体的双特异性分子及其应用
|
|
CN108264557B
(zh)
*
|
2016-12-30 |
2021-08-24 |
惠和生物技术(上海)有限公司 |
一种结合cd3和t细胞负共刺激分子的双功能分子及其应用
|
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
|
CA3221995C
(en)
|
2017-02-08 |
2024-05-28 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
|
EP3580235B1
(en)
|
2017-02-10 |
2024-05-01 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
|
KR20240060739A
(ko)
|
2017-02-20 |
2024-05-08 |
드래곤플라이 쎄라퓨틱스, 인크. |
Her2, nkg2d 및 cd16에 결합하는 단백질
|
|
US11459394B2
(en)
|
2017-02-24 |
2022-10-04 |
Macrogenics, Inc. |
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
|
|
US10918734B2
(en)
|
2017-03-27 |
2021-02-16 |
Immunomedics, Inc. |
Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
|
|
CN108659112B
(zh)
*
|
2017-03-30 |
2021-01-26 |
上海市同济医院 |
一种非对称双特异性抗体
|
|
WO2018187074A1
(en)
|
2017-04-03 |
2018-10-11 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
|
WO2018200742A1
(en)
|
2017-04-25 |
2018-11-01 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
|
|
US11447564B2
(en)
|
2017-04-26 |
2022-09-20 |
Eureka Therapeutics, Inc. |
Constructs specifically recognizing glypican 3 and uses thereof
|
|
MA48763A
(fr)
|
2017-05-05 |
2020-04-08 |
Amgen Inc |
Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés
|
|
WO2018224441A1
(en)
|
2017-06-05 |
2018-12-13 |
Numab Innovation Ag |
Novel anti-cd3 antibodies
|
|
EP3645048A4
(en)
*
|
2017-06-25 |
2021-06-16 |
Systimmune, Inc. |
MULTISPECIFIC ANTIBODIES AND THE METHOD OF MANUFACTURING AND USING THEREOF
|
|
WO2019006472A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
|
|
WO2019018629A1
(en)
|
2017-07-19 |
2019-01-24 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
|
|
MA56289B1
(fr)
|
2017-08-03 |
2022-04-29 |
Amgen Inc |
Mutéines d'interleukine-21 et méthodes de traitement
|
|
PE20212205A1
(es)
|
2017-09-08 |
2021-11-18 |
Maverick Therapeutics Inc |
Proteinas de union condicionalmente activadas restringidas
|
|
EP4141005B1
(en)
|
2017-09-08 |
2024-04-03 |
Amgen Inc. |
Inhibitors of kras g12c and methods of using the same
|
|
BR112020004902A2
(pt)
|
2017-09-15 |
2020-09-15 |
Amgen Inc. |
processo para formulação farmacêutica liofilizada de uma proteína terapêutica
|
|
CA3078974A1
(en)
|
2017-10-12 |
2019-04-18 |
Immunowake Inc. |
Vegfr-antibody light chain fusion protein
|
|
MX2020003395A
(es)
|
2017-10-13 |
2020-08-03 |
Merck Sharp & Dohme |
Composiciones y metodos para tratar linfoma difuso de celulas b grandes.
|
|
WO2019075405A1
(en)
|
2017-10-14 |
2019-04-18 |
Cytomx Therapeutics, Inc. |
ANTIBODIES, ACTIVISTIC ANTIBODIES, BISPECIFIC ANTIBODIES, AND BISPECIFICALLY ACTIVATED ANTIBODIES AND METHODS OF USE THEREOF
|
|
CN107739410B
(zh)
*
|
2017-10-18 |
2021-07-30 |
南京鼓楼医院 |
CD3单链抗体-iRGD融合蛋白、制备及其作为抗肿瘤药物的应用
|
|
EP3704153A2
(en)
|
2017-11-02 |
2020-09-09 |
Bayer Aktiengesellschaft |
Bispecific antibodies binding alk-1 and bmpr-2
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
BR112020011627A2
(pt)
|
2017-12-11 |
2020-11-17 |
Amgen Inc. |
processo de fabricação contínuo para produtos de anticorpos biespecíficos
|
|
BR112020011810A2
(pt)
|
2017-12-12 |
2020-11-17 |
Macrogenics, Inc. |
molécula de ligação cd16 x antígeno de doença, composição farmacêutica, uso da composição farmacêutica, e método para o tratamento de uma doença
|
|
MA51291A
(fr)
|
2017-12-19 |
2020-10-28 |
Xencor Inc |
Protéines de fusion il-2 fc modifiées
|
|
UY38041A
(es)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
|
|
JP2021508477A
(ja)
|
2017-12-29 |
2021-03-11 |
オンコラス， インコーポレイテッド |
治療用ポリペプチドの腫瘍溶解性ウイルス送達
|
|
EP3724223A1
(en)
|
2018-01-02 |
2020-10-21 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
|
CN107987169B
(zh)
*
|
2018-01-05 |
2021-10-08 |
阿思科力(苏州)生物科技有限公司 |
一种以ROBO1为靶点的双特异性抗体scFv及其制备和应用
|
|
UY38049A
(es)
|
2018-01-12 |
2019-07-31 |
Amgen Inc |
Anti-pd-1 anticuerpos y métodos de tratamiento
|
|
MX2020008336A
(es)
|
2018-02-08 |
2020-09-21 |
Dragonfly Therapeutics Inc |
Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
|
|
CN111787949A
(zh)
|
2018-02-15 |
2020-10-16 |
宏观基因有限公司 |
变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途
|
|
RU2020130795A
(ru)
|
2018-02-21 |
2022-03-21 |
Дзе Юнайтед Стэйтс Оф Америка, Эс Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз |
Нейтрализующие антитела к env вич-1 и их применение
|
|
CN112119099A
(zh)
|
2018-03-02 |
2020-12-22 |
Cdr-生物科技股份有限公司 |
三特异性抗原结合蛋白
|
|
JP7154634B2
(ja)
*
|
2018-03-13 |
2022-10-18 |
国立大学法人大阪大学 |
腫瘍免疫賦活剤
|
|
EP3768281B1
(en)
|
2018-03-19 |
2023-07-05 |
The Regents Of The University Of Michigan |
Compositions and methods for t-cell and cytokine activation
|
|
AU2019247415A1
(en)
|
2018-04-04 |
2020-10-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
CN112437777A
(zh)
|
2018-04-18 |
2021-03-02 |
Xencor股份有限公司 |
包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白
|
|
SG11202010163QA
(en)
|
2018-04-18 |
2020-11-27 |
Xencor Inc |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
CN112384533A
(zh)
|
2018-04-18 |
2021-02-19 |
埃克塞里艾克西斯公司 |
抗-ror抗体构建体
|
|
WO2019207051A1
(en)
|
2018-04-25 |
2019-10-31 |
Università Degli Studi Di Torino |
Medical use of combinations of non-natural semaphorins 3 and antimetabolites
|
|
WO2019213416A1
(en)
|
2018-05-02 |
2019-11-07 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
|
US11739345B2
(en)
|
2018-05-09 |
2023-08-29 |
Biomarin Pharmaceutical Inc. |
Methods of treating phenylketonuria
|
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
|
WO2019241315A1
(en)
|
2018-06-12 |
2019-12-19 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
US20210230242A1
(en)
|
2018-06-18 |
2021-07-29 |
Anwita Biosciences, Inc. |
Cytokine fusion proteins and uses thereof
|
|
MA53094A
(fr)
|
2018-07-02 |
2021-05-12 |
Amgen Inc |
Protéine de liaison à l'antigène anti-steap1
|
|
US20210301017A1
(en)
|
2018-07-30 |
2021-09-30 |
Amgen Research (Munich) Gmbh |
Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
|
|
CA3105729A1
(en)
|
2018-07-31 |
2020-02-06 |
Amgen Research (Munich) Gmbh |
Dosing regimen for bcma-cd3 bispecific antibodies
|
|
PE20211400A1
(es)
|
2018-08-03 |
2021-07-27 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cldn18.2 y cd3
|
|
MX2021002190A
(es)
|
2018-08-31 |
2021-05-14 |
Regeneron Pharma |
Estrategia de dosificacion que mitiga el sindrome de liberacion de citoquinas para los anticuerpos biespecificos cd3/cd20.
|
|
US11066476B2
(en)
|
2018-09-14 |
2021-07-20 |
Shanghai tongji hospital |
Asymmetric bispecific antibody
|
|
CN110590955B
(zh)
*
|
2018-09-17 |
2021-05-18 |
北京盛诺基医药科技股份有限公司 |
一种双特异性抗体
|
|
US20210346601A1
(en)
|
2018-09-24 |
2021-11-11 |
Amgen Inc. |
Interventional dosing systems and methods
|
|
TW202028239A
(zh)
|
2018-09-28 |
2020-08-01 |
美商安進公司 |
針對可溶性bcma之抗體
|
|
KR20210069641A
(ko)
|
2018-10-03 |
2021-06-11 |
젠코어 인코포레이티드 |
IL-12 이종이량체 Fc-융합 단백질
|
|
AR117650A1
(es)
|
2018-10-11 |
2021-08-18 |
Amgen Inc |
Procesamiento posterior de constructos de anticuerpos biespecíficos
|
|
MX2021004510A
(es)
|
2018-10-23 |
2021-06-08 |
Amgen Inc |
Calibracion automatica y mantenimiento automatico de modelos espectroscopicos de raman para predicciones en tiempo real.
|
|
SG11202104900SA
(en)
|
2018-11-20 |
2021-06-29 |
Univ Cornell |
Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
|
|
WO2020132214A2
(en)
|
2018-12-20 |
2020-06-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
|
|
TW202043253A
(zh)
|
2019-01-28 |
2020-12-01 |
美商安進公司 |
藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
|
|
US20220137010A1
(en)
|
2019-02-20 |
2022-05-05 |
Amgen Inc. |
Methods of determining protein stability
|
|
WO2020180726A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
|
US11685780B2
(en)
|
2019-03-05 |
2023-06-27 |
Takeda Pharmaceutical Company Limited |
Single domain antigen binding domains that bind human Trop2
|
|
WO2020198538A1
(en)
|
2019-03-27 |
2020-10-01 |
Amgen Inc. |
Methods of fingerprinting therapeutic proteins via a two-dimensional (2d) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
|
|
EP3962948A1
(en)
|
2019-04-30 |
2022-03-09 |
Amgen Research (Munich) GmbH |
Means and methods of treating burkitt lymphoma or leukemia
|
|
US20220227853A1
(en)
|
2019-05-03 |
2022-07-21 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
US20230085439A1
(en)
|
2019-05-21 |
2023-03-16 |
University Of Georgia Research Foundation, Inc. |
Antibodies that bind human metapneumovirus fusion protein and their use
|
|
US20220259329A1
(en)
|
2019-06-07 |
2022-08-18 |
Amgen Inc. |
Bispecific binding constructs
|
|
TW202045711A
(zh)
|
2019-06-13 |
2020-12-16 |
美商安進公司 |
生物製品製造中基於生物量之自動灌注控制
|
|
CN114269783B
(zh)
|
2019-07-02 |
2024-03-26 |
美国政府(由卫生和人类服务部的部长所代表) |
结合egfrviii的单克隆抗体及其应用
|
|
CN110623921B
(zh)
*
|
2019-08-15 |
2020-10-30 |
北京东方百泰生物科技股份有限公司 |
一种抗cd3和抗cd19的双特异性抗体注射制剂
|
|
RU2738802C1
(ru)
|
2019-08-21 |
2020-12-17 |
Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" |
Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула
|
|
GB201912681D0
(en)
|
2019-09-04 |
2019-10-16 |
Eth Zuerich |
Bispecific binding agent that binds to cd117/c-kit and cd3
|
|
AU2020345787A1
(en)
|
2019-09-10 |
2022-03-24 |
Amgen Inc. |
Purification method for bispecific antigen-binding polypeptides with enhanced protein L capture dynamic binding capacity
|
|
MX2022003933A
(es)
|
2019-10-02 |
2022-04-25 |
Domain Therapeutics |
Antagonistas del receptor ep4 de prostaglandina e2 (pge2).
|
|
WO2021074418A1
(en)
|
2019-10-16 |
2021-04-22 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
|
EP3808741A1
(en)
|
2019-10-16 |
2021-04-21 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Compounds for targeted degradation of carrier proteins and uses thereof
|
|
EP4045142A1
(en)
|
2019-10-16 |
2022-08-24 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
|
EP4054590A1
(en)
|
2019-11-04 |
2022-09-14 |
Amgen Inc. |
Methods for treating leukemia
|
|
EP3819312A1
(en)
|
2019-11-10 |
2021-05-12 |
Amgen, Inc |
Dosing regimen for anti-dll3 agents
|
|
LT3819007T
(lt)
|
2019-11-11 |
2024-10-10 |
Amgen Research (Munich) Gmbh |
Dozavimo režimas, skirtas anti-bcma agentams
|
|
US20220396599A1
(en)
|
2019-11-13 |
2022-12-15 |
Amgen Inc. |
Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules
|
|
US20230093169A1
(en)
|
2020-01-22 |
2023-03-23 |
Amgen Research (Munch) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
|
WO2021154839A1
(en)
|
2020-01-30 |
2021-08-05 |
Umoja Biopharma, Inc. |
Bispecific transduction enhancer
|
|
US20230071627A1
(en)
|
2020-02-03 |
2023-03-09 |
Amgen Inc. |
Multivariate Bracketing Approach for Sterile Filter Validation
|
|
TW202140561A
(zh)
|
2020-02-14 |
2021-11-01 |
日商協和麒麟股份有限公司 |
與cd3結合之雙特異性抗體
|
|
EP4110826A4
(en)
|
2020-02-28 |
2024-08-14 |
Shanghai Henlius Biotech Inc |
ANTI-CD137 CONSTRUCTS, MULTISPECIFIC ANTIBODIES AND THEIR USES
|
|
WO2021170067A1
(zh)
|
2020-02-28 |
2021-09-02 |
上海复宏汉霖生物技术股份有限公司 |
抗cd137构建体及其用途
|
|
CA3173981A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of npm1c-positive cancer
|
|
WO2021183861A1
(en)
|
2020-03-12 |
2021-09-16 |
Amgen Inc. |
Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
|
|
IL296601A
(en)
|
2020-03-19 |
2022-11-01 |
Amgen Inc |
Antibodies against mucin 17 and their uses
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
US20220017636A1
(en)
|
2020-05-19 |
2022-01-20 |
Amgen Inc. |
Mageb2 binding constructs
|
|
TW202210101A
(zh)
|
2020-05-29 |
2022-03-16 |
美商安進公司 |
與ｃｄ３３和ｃｄ３結合的雙特異性構建體的減輕不良反應投與
|
|
CN116529260A
(zh)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
抗cd93构建体及其用途
|
|
MX2022015376A
(es)
|
2020-06-02 |
2023-04-14 |
Dynamicure Biotechnology Llc |
Construcciones anti grupo de diferenciacion 93 (cd93) y usos de las mismas.
|
|
US20230203198A1
(en)
|
2020-06-04 |
2023-06-29 |
Amgen Inc. |
Bispecific binding constructs
|
|
TW202221029A
(zh)
|
2020-07-29 |
2022-06-01 |
美商當康生物科技有限公司 |
抗cd93之構築體及其用途
|
|
EP4200332A1
(en)
|
2020-08-19 |
2023-06-28 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
|
AU2021331170A1
(en)
|
2020-08-27 |
2023-03-23 |
Juntendo Educational Foundation |
Anti-cleaved mutant calr-cd3 bispecific antibody and pharmaceutical composition
|
|
MX2023002881A
(es)
|
2020-09-11 |
2023-04-24 |
Amgen Inc |
Materiales y metodos para reducir la agregacion de proteinas.
|
|
MX2023003041A
(es)
|
2020-09-16 |
2023-05-09 |
Amgen Inc |
Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer.
|
|
WO2022060878A1
(en)
|
2020-09-16 |
2022-03-24 |
Amgen Inc. |
Methods for treating prostate cancer
|
|
WO2022079290A2
(en)
|
2020-10-16 |
2022-04-21 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Cullin ring ubiquitin ligase compounds and uses thereof
|
|
BR112023008670A2
(pt)
|
2020-11-06 |
2024-02-06 |
Amgen Inc |
Construtos polipeptídicos ligados à cd3
|
|
CR20230235A
(es)
|
2020-11-06 |
2023-10-05 |
Amgen Res Munich Gmbh |
Construcciones polipeptídicas que se unen selectivamente a cldn6 y cd3
|
|
IL302599A
(en)
|
2020-11-06 |
2023-07-01 |
Amgen Inc |
Bispecific molecules bind multi-target antigens of increased selectivity
|
|
EP4240407A1
(en)
|
2020-11-06 |
2023-09-13 |
Amgen Inc. |
Antigen binding domain with reduced clipping rate
|
|
EP4243936A1
(en)
|
2020-11-10 |
2023-09-20 |
Amgen Inc. |
Methods for administering a bcma x cd3 binding molecule
|
|
KR20230117397A
(ko)
|
2020-12-03 |
2023-08-08 |
암젠 인크 |
다중 결합 도메인을 갖는 분자
|
|
WO2022132904A1
(en)
|
2020-12-17 |
2022-06-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies targeting sars-cov-2
|
|
IL303740A
(en)
|
2020-12-18 |
2023-08-01 |
Sanofi Sa |
Polypeptides that recruit T cells based on reactivity to alpha/beta receptors
|
|
WO2022159984A1
(en)
|
2021-01-22 |
2022-07-28 |
Bionecure Therapeutics, Inc. |
Anti-her-2/trop-2 constructs and uses thereof
|
|
JP2024506831A
(ja)
|
2021-01-28 |
2024-02-15 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
サイトカイン放出症候群を治療するための組成物及び方法
|
|
MX2023009244A
(es)
|
2021-02-09 |
2023-09-11 |
Us Health |
Anticuerpos contra la proteina espicular de coronavirus.
|
|
WO2022173689A1
(en)
|
2021-02-09 |
2022-08-18 |
University Of Georgia Research Foundation, Inc. |
Human monoclonal antibodies against pneumococcal antigens
|
|
CN114452403A
(zh)
|
2021-02-10 |
2022-05-10 |
同润生物医药(上海)有限公司 |
一种含有双功能免疫检查点/TGFβ抑制剂的药物组合
|
|
EP4305067A1
(en)
|
2021-03-09 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
CN117043173A
(zh)
|
2021-03-10 |
2023-11-10 |
美国安进公司 |
重组蛋白的纯化方法
|
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
|
|
EP4304755A1
(en)
|
2021-03-10 |
2024-01-17 |
Amgen Inc. |
Parallel chromatography systems and methods
|
|
US20240150466A1
(en)
|
2021-03-25 |
2024-05-09 |
Dynamicure Biotechnology Llc |
Anti-igfbp7 constructs and uses thereof
|
|
CN112794916B
(zh)
*
|
2021-04-08 |
2021-08-10 |
正大天晴药业集团南京顺欣制药有限公司 |
三特异性抗原结合构建体及构建方法和应用
|
|
MX2023012931A
(es)
|
2021-05-06 |
2023-11-13 |
Amgen Res Munich Gmbh |
Moleculas de union a antigeno dirigidas a cd20 y cd22 para su uso en enfermedades proliferativas.
|
|
EP4355785A1
(en)
|
2021-06-17 |
2024-04-24 |
Amberstone Biosciences, Inc. |
Anti-cd3 constructs and uses thereof
|
|
JP2024535249A
(ja)
|
2021-09-17 |
2024-09-30 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
合成ヒト化ラマナノボディライブラリーおよびｓａｒｓ－ｃｏｖ－２中和抗体を同定するためのその使用
|
|
IL311714A
(en)
|
2021-10-15 |
2024-05-01 |
Amgen Res Munich Gmbh |
Subcutaneous administration of antibodies that engage CD19-binding T cells
|
|
TW202326113A
(zh)
|
2021-10-27 |
2023-07-01 |
美商安進公司 |
使用光譜學進行的基於深度學習的預測
|
|
EP4180035A1
(en)
|
2021-11-15 |
2023-05-17 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Novel beta-lactone inhibitors of hydrolytic enzymes and their medical and non medical uses
|
|
KR20240116828A
(ko)
|
2021-12-14 |
2024-07-30 |
씨디알-라이프 아게 |
이중 mhc-표적화 t 세포 관여자
|
|
WO2023154824A1
(en)
|
2022-02-10 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that broadly target coronaviruses
|
|
AU2023224210A1
(en)
|
2022-02-23 |
2024-07-18 |
Amgen Inc. |
Cancer treatment targeting dll3
|
|
WO2023163087A1
(ja)
|
2022-02-25 |
2023-08-31 |
学校法人順天堂 |
抗変異ｃａｌｒ抗体と他の薬剤とを組み合わせてなる医薬
|
|
WO2023192881A1
(en)
|
2022-03-28 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
AU2023254191A1
(en)
|
2022-04-11 |
2024-10-17 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for universal tumor cell killing
|
|
WO2023203174A1
(en)
|
2022-04-20 |
2023-10-26 |
Proxygen Gmbh |
Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
|
|
TW202346368A
(zh)
|
2022-05-12 |
2023-12-01 |
德商安美基研究（慕尼黑）公司 |
具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
|
|
TW202413418A
(zh)
|
2022-05-27 |
2024-04-01 |
法商賽諾菲公司 |
抗bcma抗體
|
|
AR129614A1
(es)
|
2022-06-14 |
2024-09-11 |
Ablynx Nv |
Dominios variables únicos de inmunoglobulina que se dirigen al receptor de células t
|
|
WO2024030829A1
(en)
|
2022-08-01 |
2024-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
|
|
WO2024054822A1
(en)
|
2022-09-07 |
2024-03-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineered sars-cov-2 antibodies with increased neutralization breadth
|
|
TW202421650A
(zh)
|
2022-09-14 |
2024-06-01 |
美商安進公司 |
雙特異性分子穩定組成物
|
|
WO2024056758A1
(en)
|
2022-09-14 |
2024-03-21 |
Cdr-Life Ag |
Mage-a4 peptide dual t cell engagers
|
|
WO2024064826A1
(en)
|
2022-09-22 |
2024-03-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
WO2024068944A1
(en)
|
2022-09-30 |
2024-04-04 |
Sanofi |
Anti-cd28 antibodies
|
|
WO2024077044A1
(en)
|
2022-10-05 |
2024-04-11 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
|
WO2024092033A1
(en)
|
2022-10-26 |
2024-05-02 |
Amgen Inc. |
Multispecific molecules for clearance of immunoglobulins in the treatment of autoantibody-induced diseases
|
|
WO2024137381A1
(en)
|
2022-12-19 |
2024-06-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies for treating sars-cov-2 infection
|
|
WO2024138155A1
(en)
|
2022-12-22 |
2024-06-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Ebolavirus (sudan and zaire) antibodies from non-human primates and human vaccinees
|
|
US20240277844A1
(en)
|
2023-02-17 |
2024-08-22 |
Regeneron Pharmaceuticals, Inc. |
Induced nk cells responsive to cd3/taa bispecific antibodies
|
|
WO2024191785A1
(en)
|
2023-03-10 |
2024-09-19 |
Genentech, Inc. |
Fusions with proteases and uses thereof
|